Drug Trial Radar · NCT05679401
A Study With Imlifidase in Anti-GBM Disease
Last checked: Nov 19, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
50
Actual
Start
Dec 22, 2022
Primary completion
Jun 23, 2025
Study completion Feb 2, 2026
Sponsor
- Lead sponsor
- Hansa Biopharma ABIndustry
- Sponsor type
- Industry
- First posted
- Jan 11, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open-label, controlled, randomised, multi-centre Phase 3 trial evaluating renal function in patients with severe anti-GBM disease comparing imlifidase and standard of care (SoC) with SoC alone. All patients will remain in the trial for 24 months.
Conditions
- Anti-Glomerular Basement Membrane Disease
- Anti-Glomerular Basement Membrane Antibody Disease
- Goodpasture Syndrome
- Good Pasture Syndrome
Interventions
ImlifidaseDrug
Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
Plasma exchange (PLEX)Procedure
PLEX removes the patient's pathogenic anti-GBM antibodies, by replacement of deficient plasma with a replacement fluid.
Cyclophosphamide (CYC)Drug
Cyclophosphamide's main mechanism of action (i.e. crosslinking of strands of DNA and RNA) results in inhibition of protein synthesis. Hence treatment prevents formation of new anti-GBM antibodies.
GlucocorticoidsDrug
Glucocorticoids inhibit the inflammation process.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Renal function as evaluated by estimated glomerular filtration rate (eGFR) at 6 monthsTime frame: At 6 months after randomisation
Locations
48 sites in 13 countries. Site status is shown where the registry gives one.
UCLA Medical Center Plaza
Los Angeles, California
John Hopkins Medical Institution
Baltimore, Maryland
Brigham and Women's Hospital
Boston, Massachusetts
University of Minnesota Health Clinical Research Unit
Minneapolis, Minnesota
UNC Kidney Center/Division of Nephrology & Hypertension
Chapel Hill, North Carolina
The Ohio State University Wexner Medical Center
Columbus, Ohio
Medical University of Vienna, Dept of Medicine III, Division of Nephrology and dialysis
Vienna, Austria
Med Uni Graz / LKH-UNIV Klinikum Graz, Klinische Abteilung fuer Nephrologie
Graz, Stiermark, Austria
Medical University Innsbruck, Dept of Internal Medicine IV (Nephrology and Hypertension)
Innsbruck, Tyrol, Austria
UZ Leuven
Leuven, Belgium
Všeobecná fakultní nemocnice v Praze
Prague, Prague, Czechia
Rigshospitalet, Department of Nephrology
Copenhagen, Denmark
Aarhus University Hospital, Renal Medicine and Clinical Medicine
Aarhus N, Central Jutland, Denmark
Odense University Hospital, Medical Nephrology, Department Y
Odense, Region Syddanmark, Denmark
CHU Grenoble Alpes - Michallon Hospital, Nephrology, Hemodialysis, Apheresis and Kidney Transplantation
Grenoble, Auvergne-Rhône-Alpes, France
University Hospital of Marseille, Nephrology - Renal transplantation service
Marseille, Bouches-du-Rhône, France
Nouvel Hôpital Civil (University Hospital of Strasbourg)
Strasbourg, Grand Est, France
CHU Lille. Nephrology, dialysis transplantation
Lille, Haus-de-France, France
Tenon Hospital, Renal intensive care unit
Paris, Île-de-France Region, France
CHU Bordeaux, Hôpital Pellegrin, Service nephrologie, transplantation, dialyse, aphereses
Bordeaux, New Aquitaine, France
CHU de Rouen, Department of Nephrology,Transplantation, and Hemodialysis
Bois-Guillaume, Normandy, France
Hôpital Rangueil, CHU de Toulouse, Department of Nephrology and Organ transplantation
Toulouse, Occitanie, France
CHU de Nantes, Hôtel-Dieu, Le service de néphrologie et immunologie clinique
Nantes, Pays de la Loire Region, France
Charité Department of Nephrology and Intensive Care
Berlin, Germany
Universitaetsklinikum Erlangen - Medizinische Klinik 4
Erlangen, Germany
University Hospital Hamburg-Eppendorf, III Department of Medicine and Nephrology
Hamburg, Germany
LMU Klinikum, Medical Clinic IV / Department of Nephrology
Munich, Bavaria, Germany
Uniklinik RWTH Aachen
Aachen, North Rhine-Westphalia, Germany
Uniklinik Koeln-Klinik II fuer Innere Medizin
Cologne, North Rhine-Westphalia, Germany
Carl-Gustav-Carus University Hospital, Medizinische Klinik III, Nephrologie
Dresden, Saxony, Germany
Department of Renal Medicine, Cork University Hospital
Cork, Ireland
IRCCS S. Orsola - Malpighi University Hospital - Nephrology, Dialysis and Transplantation Unit (pav 15)
Bologna, Italy
ASST degli Spedali Civili di Brescia - SC Nefrologia
Brescia, Italy
IRCCS Policlinico San Martino University Hospital, Department of Internal Medicine, Division of Nephrology
Genova, Genova-Liguria, Italy
University Medical Center Groningen, Division of Nephrology
Groningen, Netherlands
Radboudumc
Nijmegen, Netherlands
Leiden University Medical Center, Department of Nephrology
Leiden, South Holland, Netherlands
University Hospital Vall d'Hebron
Barcelona, Spain
Hospital Clinic de Barcelona
Barcelona, Spain
Karolinska University Hospital
Huddinge, Sweden
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.